Article
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.
Cancer research - 1 Sept 2023
Cheng Xiaoqing, Sun Yirui, Highkin Maureen, Vemalapally Nagalaxmi, Jin Xiaohua, Zhou Brandon, Prior Julie L, Tipton Ashley R, Li Shunqiang, Iliuk Anton, Achilefu Samuel, Hagemann Ian S, Edwards John R, Bose Ron
Abstract excerpt
In metastatic breast cancer, HER2-activating mutations frequently co-occur with mutations in PIK3CA, TP53, or CDH1. Of these co-occurring mutations, HER2 and PIK3CA are the most commonly comutated gene pair, with approximately 40% of HER2-mutated breast cancers also having activating mutations in PIK3CA. To study the effects of co-occurring HER2 and PIK3CA mutations, we generated genetically engineered mice with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.